ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BI 3000202_low dose

Also written as “BI 3000202_high dose”.

Its studies are led by Boehringer Ingelheim.

Furthest: phase 1, since Mar 13, 20251 company-led study, 1 open or runningNext primary completion: Dec 10, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim11 open or runningphase 1since Mar 13, 2025Mar 13, 2025Dec 10, 2029phase 1 · NCT06878365

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 13, 2025First study: phase 1 study in Type 1 InterferonopathiesFirst studyNCT06878365 · 16 enrolled · United States, Belgium, France and more

Ahead

  1. Dec 10, 2029Primary completion: phase 1 study in Type 1 InterferonopathiesNCT06878365

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06878365Type 1 Interferonopathies · United States, Belgium, France and more1Active, not recruitingDec 10, 202916

How it is read

Names in the registry

  • “BI 3000202_low dose”, 1 entry
  • “BI 3000202_high dose”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.